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Abstract
Background: Fabry disease is a rare disorder caused by a large variety of mutations in the gene encoding
lysosomal alpha-galactosidase. Many of these mutations are unique to individual families. Fabry disease can be
treated with enzyme replacement therapy, but a promising novel strategy relies on small molecules, so called
“pharmacological chaperones”, which can be administered orally. Unfortunately only 42% of genotypes respond to
pharmacological chaperones.
Results: A procedure to predict which genotypes responsive to pharmacological chaperones in Fabry disease has been
recently proposed. The method uses a position-specific substitution matrix to score the mutations. Using this method,
we have screened public databases for predictable responsive cases and selected nine representative mutations as yet
untested with pharmacological chaperones. Mutant lysosomal alpha galactosidases were produced by site directed
mutagenesis and expressed in mammalian cells. Seven out of nine mutations responded to pharmacological
chaperones. Nineteen other mutations that were tested with pharmacological chaperones, but were not included in
the training of the predictive method, were gathered from literature and analyzed in silico. In this set all five mutations
predicted to be positive were responsive to pharmacological chaperones, bringing the percentage of responsive
mutations among those predicted to be positive and not used to train the classifier to 86% (12/14). This figure differs
significantly from the percentage of responsive cases observed among all the Fabry mutants tested so far.
Conclusions: In this paper we provide experimental support to an “in silico” method designed to predict missense
mutations in the gene encoding lysosomal alpha galactosidase responsive to pharmacological chaperones. We
demonstrated that responsive mutations can be predicted with a low percentage of false positive cases. Most of
the mutations tested to validate the method were described in the literature as associated to classic or mild classic
phenotype. The analysis can provide a guideline for the therapy with pharmacological chaperones supported by
experimental results obtained in vitro. We are aware that our results were obtained in vitro and cannot be
translated straightforwardly into benefit for patients, but need to be validated by clinical trials.
Background
Fabry Disease (FD) [ORPHANET: orpha324, OMIM:
30150] is a pan-ethnic disorder caused by mutations in the
gene encoding lysosomal alpha galactosidase [HGNC:
GLA; UNIPROT: AGAL_HUMAN,] (for a review [1]).
The classic form of the disease is characterized by angio-
keratomas, acroparesthesia, hypohidrosis, corneal opacity
in childhood or adolescence, and progressive vascular dis-
ease of the heart, kidneys and central nervous system[2].
Although FD follows X-linked inheritance, heterozygous
females can be symptomatic [3]. The reported incidence
of FD in the general population ranges from 1 in 476,000
[4] to 1 in 117,000 [5]; however this may well underesti-
mate the true proportion of affected people. Indeed, in a
large screening of Italian male newborns revealed an
o c c u r r e n c eo fm u t a t i o n si nt h eg e n ee n c o d i n gA G A La s
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its phenotypic manifestations are heterogeneous and par-
tially coincident with those of common diseases, and
because many patients develop symptoms in adolescence
or even later. An indication of the multiplicity of muta-
tions is given by the fact that 344 missense/non sense
mutations of the AGAL gene have been recorded in the
public version of HGMD [7] and even more in the profes-
sional version of the same database. Most of these muta-
tions are “private”, that is observed in only one family.
This heterogeneity of genotypes explains only part of
the heterogeneity observed in phenotypes because clinical
phenotype, age of onset and course of Fabry disease are
highly variable, even within the same family [8]. At pre-
sent the treatments of Fabry disease are symptomatic and
life-long. Enzyme replacement (ERT) has already been
introduced into medical practice and is considered
“the clinical gold standard”. This therapy requires intra-
venous infusions of purified AGAL produced by geneti-
cally engineered cell lines every 2 weeks [9]. Treatment
with pharmacological chaperones (PCs), in particular
1-deoxy-galactonojirimycin is in phase three clinical
trials. 1-deoxy-galactonojirimycin, also known as DGJ,
migalastat hydrochloride orA T 1 0 0 1i sa ni m i n os u g a r
that resembles galactose. The therapeutical approach
with PCs relies on competitive inhibitors of AGAL that
bind and stabilize the enzyme, increasing its total cellular
levels, as shown in cultured cells and in vivo [10-12]. In
theory PCs represent a useful alternative to ERT because
they do not cause adverse immunological reactions and
can be administered orally. In practice therapy with PCs
is limited because only some mutations can be rescued
by these drugs [13]. It has been observed that usually, but
not necessarily, late-onset forms, as well as mutations
that do not occur in the catalytic domain of AGAL,
respond to 1-deoxy-galactonojirimycin.
We have recently proposed a method to predict which
mutations in AGAL are responsive to 1-deoxy-galactono-
jirimycin. We have trained a classifier using published data
concerning responsive and non responsive mutations
[14-18] and evaluated 87% accuracy by cross validation. In
this paper we extended this study by testing the method
on mutations not included in the classifier training.
Results
Selection of mutations
Three-hundred AGAL mutant sequences from Uniprot/
S w i s s p r o t[ 1 9 ]a n dH G M D[ 7 ]w e r ea n a l y z e dw i t ht h e
method described previously [20]. This method relies on a
Position Specific Substitution Matrix (PSSM) calculated
from sequences homologous to AGAL. It assigns a score
to a mutation taking into account the degree of conserva-
tion of the wild type amino acid in homologous sequences
and the specific substitution that is introduced: if the new
amino-acid is present in homologous species, a less nega-
tive score is obtained. The method was benchmarked and
a threshold was set: scores equal or higher than -1 were
associated with mutations responsive to 1-deoxy-galacto-
nojirimycin with 87% accuracy (correctly predicted
responsive mutations plus correctly predicted non respon-
sive mutations divided by total number per 100).
Among the AGAL mutations present in HGMD [7] and
as yet untested for their responsiveness to PC, we found
35 mutations scoring 0 or -1. We selected 4 representative
mutations with score 0, and 5 representative mutations
with score = -1 for further analysis.
This is a minimal set, but it is a good representation of
the different types of mutations that can be encountered
in AGAL. The set includes mutations occurring in differ-
ent structural domains of the protein (TIM or beta), in dif-
ferent elements of secondary structure (alpha helix, beta
strand, coil, polyproline II), at solvent exposed or non
exposed sites. We also included mutations with different
thermodynamic stability (assessed with MUPRO [21] or
SDM [22,23]) and the rare case of a mutation affecting a
non conserved residue of the active site (table 1). Mutant
enzymes were produced by site directed mutagenesis and
expressed transiently in COS-7 cells.
Activity of mutants with and without pharmacological
treatment in vitro
Consistent with the clinical phenotype (classic FD) asso-
ciated with mutations A230T [24], R301P [25], L310F
[26], E341D [27] and V269M [28], the activity of the
enzymes carrying these mutations was very close to the
background i.e. the activity of COS-7 cells transfected with
the void vector (figure 1). Four cases of hemizygotes
affected with variable symptoms, ranging from severe to
mild and with low to intermediate residual AGAL activity,
were described for T410A [29]. This mutation, had a resi-
dual activity just above background when expressed in
COS-7 cells. For L300F [30] we also measured residual
activity above background, but no information is given on
whether the associated phenotype of the patient was clas-
sic or mild. We measured residual activity above back-
ground for D244H [31] which was identified in a
heterozygous female whose affected sons had the classic
phenotype and for Q280K [32].
Most mutations associated to Fabry disease have been
observed in single families and for this reason both the
classification based on symptoms and the correlation with
residual activity can be difficult.
The comparison of enzymatic activity of mutants with
that of wild type expressed in COS-7 is summarized in
figure 1; red bars indicate results obtained without the
treatment with 1-deoxy-galactonojirimycin and blue bars
indicate results obtained culturing the cells with 20 micro-
molar 1-deoxy-galactonojirimycin for 48 hours.
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jirimycin enhances alpha-galactosidase activity, even in
the cells transfected with the wild type AGAL construct,
since it was demonstrated, using scanning calorimetry,
that wild type AGAL is stabilized by 1-deoxy-galactono-
jirimycin at both neutral and acidic pH [33]. Conditions
that stabilize proteins, such as the presence of PCs, can
increase the fraction of newly folded enzyme exported
from the endoplasmic reticulum.
Seven out of nine mutations recovered 15% of wild
type activity or more (figure 1), the exceptions being
A230T and E341D. Although severity of Fabry disease
correlates with the level of residual activity, it is difficult
to determine the minimum level necessary to prevent
the classic phenotype.
In order to set such a level we collected two groups of
data from literature. The first group comprises 72 muta-
tions whose residual activity has been assayed in fibro-
blasts derived from male patients [15], the second group
comprises 21 mutations produced by site directed muta-
genesis and assayed in COS cells [17,18]. The authors of
the original papers provided the phenotype associated
with each mutation. In both groups, mutations with a
residual activity higher than 12% were associated with
atypical/late phenotype, the only exception being E59K
with 19 ± 3% residual activity [15]. This mutant has an
Table 1 Characteristics of the Fabry mutations tested by expression in COS-7 cells
Mutant: nucleotide Amino acid fold increase PSSM MUPRO SDM PSAmc PSAsc sec_stru domain Active site Pheno type ref
c.688G > A p.A230T 2.1 0 -2.33 -0.48 4 64.8 P(5) TIM Yes Classic [24]
c.730G > C p.D244H 3.3 -1 -1.74 0.379 18.6 48.7 A(11) TIM No Classic [31]
c.805G > A p.V269M 2.5 0 -0.77 -0.212 3.2 0 O(12) TIM No Classic [28]
c.838C > A p.Q280K 3.1 0 -1.00 -1.126 0 17.3 A(14) TIM No Classic [32]
c.898C > T p.L300F 5.8 -1 -1.60 -0.732 9.9 0 O(6) TIM No ? [30]
c.902G > C p.R301P 3.7 -1 -1.68 -1.228 65.2 17.5 O(6) TIM No Classic [25]
c.928C > T p.L310F 8.9 0 -1.34 -1.334 1.7 5.1 A(5) TIM No Classic [26]
c.1023A > C p.E341D 2.2 -1 -0.88 -1.055 0 0 B(9) beta No Classic [27]
c.1228A > G p.T410A 3.5 -1 -1.47 0.215 0 0 O(1) beta No Variant [29]
Mutations tested by transient transfection are listed together with their responsiveness to 1-deoxy-galactonojirimycin expressed as fold increase, the scores
obtained by PSSM (assessment of conservation in homologous sequences), the scores obtained by SDM and MUPRO (assessment of the effect of mutations on
thermodynamic stability), % main chain accessibility (PSAmc), % side chain accessibility (PSAsc), occurrence in A alpha-helix, B beta strand, P poly-proline II or O
other (with the length of the secondary structure in which the mutation occur in brackets), occurrence in specific structural domains and in the active site.
Severity in patients was deduced from literature and the reference paper is reported alongside.
Figure 1 Alpha-galactosidase activity resulting from 1-deoxy-galactonojirimycin administration in transfected COS-7 cells.F o u r
independent experiments performed in duplicate for 1-deoxy-galactonojirimycin (20 micromolar) administration in COS-7 transfections were
performed. Values are expressed as percentage of COS-7 cells transfected with wild type. Standard deviations is indicated by bars and differences
that are statistically significant are flagged by asterisks (p < 0.05:*; p < 0.01: **; p < 0.005:***; p < 0.001 :****)
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dual activity at the saturating conditions which are gener-
ally used to assay enzymes in vitro, but not at the
physiological concentrations of substrate present in the
cell.
In consideration of the error associated with residual
activity measures, we rounded by excess the minimum
level sufficient to prevent classic phenotype to 15%. Our
threshold was set quite cautiously, but does not differ
significantly from that estimated by Fan and Ishii who
stated “one would assume that residual enzyme activity
greater than 10% of normal in hemizygote patients
m i g h tb es u f f i c i e n ta tr e d u c i n gt h em a j o r i t yo fc l i n i c a l
symptoms” [34].
In women, the residual enzymatic activity differs from
cell to cell due to X-inactivation and so values measured
in serum might not correlate with the severity of the
disease; nonetheless, raising residual activity above a
minimal level in cells expressing the mutant allele, can
still be beneficial for female patients.
The strongest response in terms of ratio between cel-
lular activity obtained with or without treatment with 1-
deoxy-galactonojirimycin was observed with L300F
(table 1). Unfortunately in this case we were not able to
deduce from the original paper the phenotype of the
affected patients, but we learned from literature [15]
that a mutation affecting the same site, L300P, is asso-
ciated with classic phenotype and is responsive to 1-
deoxy-galactonojirimycin with an even higher increase
of activity.
Western blot
Human alpha-galactosidase is synthesized as a precursor
of 50 kDa, but it is converted into a mature form of 46
kDa. A detailed analysis of Ishii and coworkers [2]
demonstrated that when AGAL mutants are correctly
processed into a 46 kDa form, they are also transferred
into lysosomes. We first compared the migration of
wild-type AGAL expressed in COS-7 cells, with and
without treatment with PCs, to that of the precursor
form (Fabrazyme
®). In order to have bands of similar
intensity, we loaded 20 micrograms of COS-7 extracts
non treated with 1-deoxy-galactonojirimycin, 15 micro-
grams of COS-7 extract treated with 1-deoxy-galactono-
jirimycin (48 hours 20 micromolar), 20 micrograms of
COS-7 extracts from cells transfected with void vector
to which we added 20 nanograms of Fabrazyme
®). and
20 nanograms of Fabrazyme
®). AGAL bands were
revealed by Western blot. As predicted, AGAL
expressed in COS-7 migrated as 46 kDa band while the
precursor migrated as 50 kDa band (figure 2 panel A).
We then tested the migration of the mutants.
D244H, V269M, Q280K, L300F, R301P, L310F,T410
migrated as the wild type enzyme (figure 2 panel B and C)
and upon treatment of cells with 1-deoxy-galactonojirimy-
cin (48 hours 20 micromolar), the same protein band was
observed with enhanced intensity. In figure 2 panel D the
bands produced by those mutants displaying a low relative
increase of activity upon treatment with the drug (fold
increase <3 in table 1) were detected with longer acquisi-
tion time. A230T shows a faint band corresponding to the
precursor form of AGAL which is not induced by the
treatment with 1-deoxy-galactonojirimycin, V269M and
E341D on the other hand, show bands corresponding to
that of the mature form upon induction although the
intensity of the band of the latter mutant is very weak.
The results of Western blot analysis demonstrates that
treatment with the drug enhances the quantity of AGAL
in the cell possibly stabilizing it and preventing its
degradation.
Analysis of mutants
We measured the ratio of the cellular activity of AGAL
mutants treated or not treated with 1-deoxy-galactono-
jirimycin and expressed it as fold increase (table 1).
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Figure 2 Effect of 1-deoxy-galactonojirimycin on various
mutant of alpha-galactosidase expressed in COS-7 cells.
Western blot analysis. Cells were cultured in the presence (+) or
absence (-) of 20 uM 1-deoxy-galactonojirimycin for 2 days prior to
western blot analysis. Panel A: WT-, COS-7 transfected with wild
type AGAL (20 micrograms of cell extract); WT+, COS-7 transfected
with wild type AGAL and treated with 20 micromolar 1-deoxy-
galactonojirimycin (15 micrograms of cell extract); preWT/COS, COS-
7 tranfected with void vector (20 micrograms) plus alpha-
galactosidase precursor form (Fabrazyme
® 20 nanograms), preWT,
alpha-galactosidase precursor form (Fabrazyme
® 20 nanograms); M,
marker;. Panel B,C,D: COS-7 transfected with void vector (COS7),
wild-type (WT) or mutant alpha-galactosidase vectors (10
micrograms) not treated (-) or treated with 1-deoxy-
galactonojirimycin (+).
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and PSSM score for each mutant and reported them
together with the clinical phenotype obtained from lit-
erature (table 1). As previously explained, the mutations
were chosen among those present in HDMG as repre-
sentative cases with a relatively high score (0 or -1)
obtained with the method based on PSSM construction.
:AGAL is a dimeric protein, each subunit being
formed by a TIM barrel catalytic domain (res 32-325)
and a small 8 stranded beta domain (res 326-429)
whose function is not known [33]. We showed that
occurrence in the TIM barrel catalytic domain does not
prevent responsiveness to 1-deoxy-galactonojirimycin.
This does not contradict the observation reported in lit-
erature [15] that mutations in the beta domain are
mainly responsive, but reinforces the idea that muta-
tions responsive to 1-deoxy-galactonojirimycin are wide-
spread in the enzyme structure.
We listed structural features such as main chain and
side chain accessibility of the affected site, type and
length of the secondary structure where mutation occurs,
the effect of the mutation on thermodynamic stability
assessed with a method which rely on 3D-structure, such
as SDM [22,23], or with a method which relies only on
the sequence of the affected protein and the nature of the
mutation, such as MUPRO [21].
All the mutants respond to 1-deoxy-galactonojirimycin
in terms of fold increase (table 1), but if we consider the
percentage of activity in the presence of 1-deoxy-galac-
tonojirimycin compared to that of wild type, E341D and
A230T might not recover enough activity to revert clas-
sic phenotype (figure 1). E341D is not conserved in
homologous sequences and hence gets a high score by
the PSSM, nonetheless it has a small response. An
explanation exists for this since E341 occurs in a com-
pletely buried site and its mutation to aspartate is nega-
tively scored by SDM [22,23], with a medium/severe
a d v e r s ee f f e c to nt h e r m o d y n a m i cs t a b i l i t y( t a b l e1 ) .A s
demonstrated in our previous paper [20], SDM scores
and solvent accessibility correlate with responsiveness;
therefore co-occurrence of a low SDM score and low
solvent accessibility explains the low response of E341D
to the drug.
In contrast, A230 is exposed to solvent and its muta-
tion to Threonine is mildly destabilizing.
Analysis of the enzyme active site explains why A230T
responds very little to 1-deoxy-galactonojirimycin. A230
is not directly implicated in catalysis, but it is flanking
D231, a proton donor that is essential for the hydrolysis
of the substrate.
In addition, A230 belongs to a stretch of amino acids
(229-232) that adopts a poly-proline II helix structure:
this kind of secondary structure is quite rare in proteins
and is often associated to special functions [35]. Figure 3
shows the active site of AGAL and the side chain of resi-
dues binding 1-deoxy-galactonojirimycin like D231, the
backbone of aminoacids 229-232 and the side chain of
A230 are shown. The characteristic three fold symmetry
of the polyproline-helix can be seen from the spatial dis-
position of the carbonyl bonds. Although a direct proof
could come only solving the X-ray structure of A230T,
we can tentatively suggest that this secondary structure is
affected by the mutation.
Close proximity to an essential residue and occurrence
in a poly-proline helix explains why the mutation to
Threonine results in a non responsive enzyme: muta-
t i o n sa f f e c t i n gt h ea c t i v es i t es h o u l db eu n a b l et ob i n d
the chaperone.
In this study we tested our method on mutations that
had not been included into the training set and in parti-
cular on cases which our method predicted as responsive
to the pharmacological therapy. Given that a therapy of
general applicability (ERT) is already available, it is very
important to prove that the percentage of false positive
cases is low. We found that of nine AGAL mutants get-
ting a PSSM score of 0 or -1 and expressed in cultured
cells, seven responded to 1-deoxy-galactonojirimycin. In
order to further validate the precision of our method, we
looked in the literature for additional mutations which
had been tested with 1-deoxy-galactonojirimycin, but not
used in the training set of our method. We gathered 11
responsive and 8 non responsive cases and calculated
their PSSM scores (table 2). In this set, the five mutations
scoring -1 or 0 were all responsive, those scoring -2 were
mostly (4/6) responsive, those scoring less than -2 were
mostly (6/8) non responsive.
We calculated structural and functional characteristics
and the PSSM score for each mutant (table 2) together
with the responsiveness to 1-deoxy-galactonojirimycin “in
vitro” obtained from literature. As A230T (table 1), three
mutations in this set affect the active site and are, invari-
ably, non responsive to 1-deoxy-galactonojirimycin.
This result reinforces the caveat which should always
be born in mind when considering PCs for clinical appli-
cations: the function of a chaperone is to stabilize the
conformational structure of the enzyme, prevent its
degradation before it reaches the operative location, but
in no case PCs can restore the activity of an enzyme
whose active site has been affected by a mutation.
Conclusions
A surprising high percentage of missense mutations is
found in a relatively small protein such as lysosomal
alpha galactosidase for reasons that are still unclear. A
survey of the list of human proteins associated with dis-
eases provided by Uniprot (http://www.uniprot.org/docs/
humpvar release 8_2_2011) provides a flavour of the
peculiarity of AGAL_HUMAN and reveals that,
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highest ratio between reported missense mutations and
chain length; only chain A and B of haemoglobin, Gap
junction beta-1 protein (associated with Charcot-Marie-
Tooth disease), Transthyretin (associated with amyloido-
sis type 1) and Phenylalanine-4-hydroxylase (associated
with phenylketonuria) have higher rates. The number of
missense mutations is likely to increase, since an average
of 20-25 novel mutations per year have been identified in
the last decade in Fabry disease cases and others are
expected from the AGAL mutation screening of the gen-
eral population.
After genotyping Fabry disease cases, clinicians will
face a multitude of different molecular defects and will
have to counsel patients about the best therapy to adopt.
Enzyme replacement therapy has general applicability,
but pharmacological chaperones offer several advantages.
This is especially true in the late on-set forms of the dis-
ease, when a therapy to prevent the accumulation of gly-
cosphingolipids and hence to delay organ damage, has to
be suggested to patients who still have little or no
symptoms.
In order to counsel Fabry patients clinicians need to
know conditions that are sufficient to make mutations
responsive to PC. Regrettably only conditions that are
sufficient, but not necessary, to make mutations non
responsive to PC are clearly identifiable.
By analyzing in silico 96 mutations, we previously pro-
posed a method that calculates a score based on the
construction of PSSM [20]. We have now tested this
method on 14 new mutations scoring >-2 and found
that 12 (86%) of them were responsive to 1-deoxy-galac-
tonojirimycin. These values differ significantly (Fisher
two tailed p value <0.01) from the percentage of muta-
tions (42%) recovering activity (>15% of wild type) in
screenings carried out by independent laboratories on
randomly collected mutations.
In figure 4, panel A, we summarize the results obtained
on all AGAL mutants tested “in vitro“ so far which were
responsive to 20 micromolar 1-deoxy-galactonojirimycin
(or had an EC50 <20 micromolar). The responsive cases
are 86% among the mutations scoring >-2 and only 20%
among the mutations scoring <-2 and no responsive cases
were observed so far below -3. The correlation between
percentage of responsive mutations and PSSM scores in
the range +1/-4, is very high and statistically significant,
(Pearson correlation coefficient r = 0.96 with two-tailed p-
value 0.003) figure 4 panel B.
Our guideline for clinicians is the following: if a new or
as-yet untested AGAL mutation has a PSSM score >-2 it is
likely to be responsive to 1-deoxy-galactonojirimycin; if it
gets a PSSM <-2 it is likely to be non responsive; if it gets
PSSM scores -2 it is in a twilight zone where a case by case
judgment is necessary. We are aware that a bioassay on
cells derived from patients carrying a specific mutation
represents a more convincing proof of the efficacy of the
treatment with 1-deoxy-galactonojirimycin in any given
case. However, we feel that the simplicity and low cost of
Figure 3 The active site of human lysosomal alpha-galactosidase. The active site of alpha-galactosidase is sketched as a wireframe coloured
by atom type showing the side chains of residues which directly bind 1-deoxy-galactonojirimycin (D92, D93, D170, D231,E203, K168, R227), the
side chains of C142, A230,S297 and the backbone of the peptide, ranging from 229 to 232, in poly-proline II helix conformation. Arrows run
alongside carbonyl bonds. 1-deoxy-galactonojirimycin is coloured in green.
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by clinicians.
Methods
Selection and construction of mutants
We collected 13 homologous AGAL sequences from
Uniprot/Swissprot [19]; these had E-value <10
-50 and
sequence identity ranging from 95% to 30%. A Position
Specific Substitution Matrix (PSSM) was built from this
set of sequences running BLASTPGP (BLASTP2.2.18) in
PSI-BLAST mode flagging on the output of a check-
point file. The PSSM was exploited in a second round
of BLASTPGP to calculate net scores for human AGAL
mutants [36] obtained by HGMD [7]. Nine mutations
were selected among those obtaining score 0 and -1 that
had not been previously tested experimentally with 1-
deoxy-galactonojirimycin.
The clone SC319065, which contains the full length
cDNA for wild type AGAL_HUMAN inserted into the
expression vector pCMV6-AC, was purchased from Ori-
gene (Rockville, MD, USA). Mutations were introduced
with two consecutive PCR reactions. In the first round of
amplifications, two reactions were set up, one contained
the outmost forward oligo (ECOR1_FORWARD) and the
specific reverse mutant oligo (table 3) and the other con-
tained the outmost reverse oligo (XHO1_REVERSE) and
the forward specific mutant oligo (table 3). In the second
round of amplifications, the purified products of the first
PCR reactions were used as templates and the outmost
forward and reverse oligos were used as primers. The
amplifications were performed for 28 cycles using the fol-
lowing conditions: 95°C for 10 min, 94°C for 30 sec, 60°C
for 30 sec, 72°C 30 sec, and 72°C for 5 min with 0.6 μMo f
each primer. After the second round, amplified fragments
were purified, digested with ECORI and XHOI and
inserted into pCMV6-AC. Mutant constructs were verified
by sequencing.
Transfection into COS-7 cells
COS-7 were cultured in DMEM containing 10% FBS at
37°C and 5% CO2. The cells were transfected with indivi-
dual pCMV6-AC plasmids containing wild type or mutant
AGAL-encoding ORF using the LipofectAMINE2000
cationic lipid reagent.
Four micrograms of plasmid DNA in 0.5 ml Opti-MEM
(Invitrogen) were mixed with 18 microliters LipofectA-
MINE2000 reagent (Invitrogen) in 0.5 ml Opti-MEM
(Invitrogen) and incubated for 20 min at room tempera-
ture. During this time, COS-7 cells were harvested by
trypsin treatment and resuspended in DMEM containing
10% FBS.
COS-7 in suspension (4 ml) were added to transfection
mix solution, distributed into two wells of a six-well plate
at 60% confluency and allowed to adhere overnight. The
Table 2 Characteristics of the Fabry mutations gathered from literature
Mutant: nucleotide aminoacid PSSM MUPRO SDM PSAmc PSAsc sec_stru domain ACT.SITE resp ref
c.58G > C p.A20P -2 -2.00 NA NA NA NA leader pep. No Yes [2]
c.153G > A p.M51I -2 -0.51 0.414 0.0 27.1 O(15) TIM No Yes [41]
c.155G > A p.C52Y -5 -1.37 -1.582 29.5 27.3 O(15) TIM No No [14]
c.194G > C p.S65T -1 -0.85 0.330 0.0 25.5 O(15) TIM No Yes [42]
c.214A > G p.M72V -1 -0.27 -1.232 0.0 0.0 A(10) TIM No Yes [2]
c.426C > G p.C142W -7 -0.91 0.167 64.6 33.8 O(15) TIM Yes No [18]
c.436C > T p.P146S -3 -0.44 -0.983 1.4 19.5 O(15) TIM No Yes [2]
c.467C > T p.A156V -1 -0.26 -0.357 0.0 0.6 A(11) TIM No Yes [2]
c.496C > G p.L166 0 -1.18 -0.244 0.0 3.9 B(5) TIM No Yes [2]
c.548G > C p.G183A -2 -0.85 2.330 1.5 5.3 A(18) TIM No Yes [14]
c.581C > T p.T194I -2 -0.57 2.008 76.0 2.6 A(18) TIM No Yes [43]
c.647A > G p.Y216C -3 -1.16 -2.319 11.3 1.9 A(6) TIM No Yes [14]
c.692A > G p.D231G -2 -2.24 -2.726 49.3 66.7 P(5) TIM Yes No [18]
c.796G > A p.D266N -3 -1.30 -0.754 12.8 4.4 O(12) TIM No No [18]
c.868A > C p.M290L 0 -0.18 0.486 0.5 2.9 A(14) TIM No Yes [44]
c.890C > T p.S297F -3 -0.73 2.714 0.0 0.0 B(7) TIM Yes No [18]
c.1118G > A p.G373D -3 -0.98 0.251 0.5 0.3 O(12) beta No No [2]
c.1117G > A p.G373S -3 -1.18 -0.256 0.5 0.3 O(12) beta No No [2]
c.1244T > C p.L415P -2 -2.06 -1.232 0.0 0.7 B(9) beta No No [45]
Mutations not included in the training set of the predictive method are listed with the scores obtained by PSSM (assessment of conservation in homologous
sequences), the scores obtained by SDM and MUPRO (assessment of the effect of mutations on thermodynamic stability), % main chain accessibility (PSAmc), %
side chain accessibility (PSAsc), occurrence in A alpha-helix, B beta strand, P poly-proline II or O other (with the length of the secondary structure in which the
mutation occur in brackets), occurrence in specific structural domains and in the active site. Responsiveness in vitro to 1-deoxy-galactonojirimycin was deduced
by literature and the reference paper is reported alongside.
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Page 7 of 10efficiency of transfection was increased by treatment with
cloroquine 100 micromolar (SIGMA, Milan, Italy)
[14,37]. The efficiency of the transfection was calculated
by cotrasfecting an equal amount of pMIR vector
(AppliedBiosystem/Ambion, Italy) containing the lucifer-
ase gene and assaying the reporter gene activity under
standard conditions using ONE-Glo™ Luciferase Assay
System (Promega, Italy). A 3-fold increase in efficiency
was measured in the presence of cloroquine.
The medium was substituted by fresh DMEM, 10% FBS
(3 ml) and in one well 20 micromolar 1-deoxy-galactono-
jirimycin was added whereas in the other was not. After a
48 hr incubation, the cells were washed in PBS (5 times),
scraped and harvested by centrifugation. Dry pellets were
resuspended in 200 microliters of water and lysed by
freeze-thawing. Four independent transfections were car-
ried out.
Water-soluble extracts were used for enzyme assays or
western blot.
Alpha-galactosidase assay
Cell lysates (2 microliters) were added to 38 microliters
of AGAL assay buffer (sodium citrate 27 mM-sodium
phosphate dibasic 46 mM, 4-methylumbelliferyl-alpha-
Figure 4 Distribution of responsive and non responsive alpha-galactosidase mutants and correlation of responsiveness with scores
assigned with a Position Specific Substitution Matrix. Panel A: Distribution of responsive (blue bars) and non responsive (red bars) alpha
galactodidase mutants over Position Specific Substitution Matrix scores. Panel B: Percentage of responsive alpha-galactosidase mutants as a
function of Position Specific Substitution Matrix scores
Table 3 Mutated oligonucleotides for site direct mutagenesis
oligo forward reverse
ECOR1_RWARD GCAGAGCTCGTTTAGTGAACCGTCAGAATT
XHO1_REVERSE CTGTTCAGGAAACAGCTATGACCGCGGCCG
A230T GCGAAATTTTACTGACATTGATGATTCCTGG CAATGTCAGTAAAATTTCGCCAGTGATTGC
E341D AAGTGTGGGATCGACCTCTCTCAGGCTTAGC GAGAGGTCGATCCCACACTTCAAAGTTGTCTC
L310F AGCCAAAGCTTTCCTTCAGGATAAGGACGTA CCTGAAGGAAAGCTTTGGCTTGAGGGCTGA
V269M GATATGTTAATGATTGGCAACTTTGGCCTC TTGCCAATCATTAACATATCTGGGTCATTCC
T410A ATAAATCCCGCAGGCACTGTTTTGCTTCAG ACAGTGCCTGCGGGATTTATGTGACTTCTTA
L300F TCTAATGACTTCCGACACATCAGCCCTCAA GATGTGTCGGAAGTCATTAGACATGAATAAAG
R301P TGACCTCCCACACATCAGCCCTCAAGCCA GGCTGATGTGTGGGAGGTCATTAGACATGAAT
D244H GTATCTTGCACTGGACATCTTTTAACCAG GATGTCCAGTGCAAGATACTCTTTATACTTT
Q280K CTGGAATCAGAAAGTAACTCAGATGGCCCTC TGAGTTACTTTCTGATTCCAGCTGAGGCCAA
Underlined bases correspond to the mispairings with the normal alpha-galactosidase sequence used to introduce the mutations in the pCMV6-AC-AGAL vector
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Page 8 of 10D-galactopyranoside 5 mM and N-acetyl-D-galactosa-
mine 100 mM, pH 4.5) and incubated for 1 h at 37°C.
All chemicals were obtained from Sigma. The reaction
was stopped by adding 360 microliters of 1 M sodium
carbonate buffer [15]. Fluorescence was detected using a
fluorescence spectrophotometer (Cary Eclypse-Varian)
at 355 nm excitation and 460 nm emission.
A 4-methylumbelliferone standard curve ranging from
5 nM to 25 micromolar was run in parallel for conver-
sion of fluorescence data to AGAL activity expressed as
nmol/mg protein per min.
Statistical analysis
Standard deviations and p values in figure 1 (paired two-
tailed Student ‘s t-test) were obtained using Microsoft
Excel (Microsoft Office professional 2010).
Western blot analysis
Western blot analysis for the detection of AGAL was per-
formed by using polyclonal antibody produced in rabbit
(Abcam 70520) and HRP-coniugated anti-rabbit IgG
antibody produced in goat (Bio-Rad 1706515).
After SDS-PAGE (4-20% acrylamide), proteins were
transferred to a PVDF membrane. The membrane was
blocked with 5% (w/v) non-fat dried skimmed milk in blot
solution at 4°C overnight, then treated with the primary
antibody diluted in a blot solution 1:500 for 1 hour at
room temperature. After washing with an excess of blot
solution, the membrane was treated with the secondary
antibody diluted in the blot solution 1:2000 for 1 hour at
room temperature. After washing, the detection was per-
formed by using the Immun-Star WesternC chemilumi-
nescence detection kit (Bio-Rad). GAPDH was revealed
using with mouse monoclonal anti lapine GAPDH (AbD
seroTec (cat:4699-9555) 1:20000. Fabrazyme
® (agalsidase-
beta; Genzyme Europe B. V., NL). All other chemicals
were from Bio-Rad.
In silico characterization
Models of all AGAL mutants are constructed using PDB
file 3GXT as template [33]. Side chains were substituted
with the program ANDANTE, which predicts side-chain
conformations by use of environment-specific substitu-
tion probabilities and a high-quality rotamer library [38].
SDM [22,23] uses a set of conformationally constrained
environment-specific substitution tables and calculates the
difference in the stability scores for the folded and
unfolded state of each mutant and the wild-type protein. It
uses as inputs the mutants generated with ANDANTE and
the structure of the wild type enzyme.
Residue percent accessibility in AGAL dimer structure
(3GXT) was calculated with PSA v2.0 [39] which uses the
rolling probe algorithm [40]. We assigned each residue in
the wild type AGAL structure 3GTX to alpha helices,
beta sheets, poly-proline helix or other with the program
SEGNO [35].
MUPRO1.1 was run locally, using as inputs only
AGAL sequence, the position affected by the mutation,
the original and the mutant amino-acid.
The programs SDM [22,23], ANDANTE and PSA
were kindly provided by T. Blundell and collaborators.
MUPRO1.1 [21] was kindly provided by Dr J. Cheng.
Abbreviations
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